Pfizer Recalls Levoxyl Tablets Due to Subpotency Concerns

Pfizer has recalled two lots of Levoxyl (levothyroxine sodium) 175 mcg tablets, totaling 15,949 bottles, after stability tests showed the medication was subpotent. This Class II recall, initiated on September 29, 2026, and classified by the FDA on October 16, 2026, means the tablets may not deliver the intended therapeutic effect.